Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01698307 · ClinicalTrials.gov registry record · Phase 4

Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy

A Phase 4 study, sponsored by Alimentiv.

Completed
Registry status
Phase 4
Development phase
1,095
Enrollment target

NCT01698307: Completed Phase 4 study, sponsored by Alimentiv.

NCT01698307 is a Phase 4 study that has completed, run by Alimentiv. The registered enrollment target is 1,095 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (111% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01698307, a Phase 4 study, has completed, sponsored by Alimentiv.

COMPLETED
Registry status
Phase 4
Development phase
1,095 participants
Enrollment target

Study Summary

Assess if the implementation of an enhanced treatment algorithm will improve the management Crohn's Disease compared to a conventional Step-care approach.

Primary Outcome

Crohn''s Disease (CD)-related complications include (1) CD-related surgeries and non-surgical CD events (such as disease flare, bowel obstruction, and bowel damage events (such as symptomatic bowel obstruction, fistula, abscess and CD related hospitalizations and 2) complications and hospitalizations related to CD medications or procedures.

Interventions

  • OTHER Enhanced Treatment Algorithm
  • OTHER Conventional Step-care Algorithm

Trial Details

FieldValue
Enrollment Target 1,095 participants
Start Date 2014-03-28
Est. Completion 2020-04-16
Phase Phase 4
Alimentiv

7 total trials

What the finished NCT01698307 record still lists

NCT01698307 is an interventional study that assigns participants to a tested intervention. Its 1,095 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (111% higher).

The record links to 0 conditions, and to 2 interventions - of which Enhanced Treatment Algorithm is the first listed.

NCT01698307 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01698307 about?

NCT01698307 is a clinical study titled "Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy". Assess if the implementation of an enhanced treatment algorithm will improve the management Crohn's Disease compared to a conventional Step-care approach.

What is the current status of trial NCT01698307?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,095 participants. The study started on 2014-03-28. Estimated completion is 2020-04-16.

What interventions are being tested in trial NCT01698307?

The interventions under investigation include: Enhanced Treatment Algorithm (OTHER), Conventional Step-care Algorithm (OTHER).

Who is sponsoring clinical trial NCT01698307?

This trial is sponsored by Alimentiv, which has 7 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01698307's enrollment target sits among peer trials

1,095 65th of 2000 higher than 1,936 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06191744 · 1,095 participants · Phase 3

    Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

  • NCT03754114 · 1,094 participants · NA

    Brain Oxygen Optimization in Severe TBI, Phase 3

  • NCT06118983 · 1,094 participants · NA

    Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)

  • NCT06585241 · 1,094 participants · Phase 4

    A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01698307, the US trial registry maintained by the National Library of Medicine. NCT01698307 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.